Menu
GeneBe

ALK

ALK receptor tyrosine kinase, the group of Receptor tyrosine kinases|CD molecules

Basic information

Region (hg38): 2:29192773-29921586

Links

ENSG00000171094NCBI:238OMIM:105590HGNC:427Uniprot:Q9UM73AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • neuroblastoma, susceptibility to, 3 (Strong), mode of inheritance: AD
  • neuroblastoma, susceptibility to, 3 (Strong), mode of inheritance: AD
  • neuroblastoma, susceptibility to, 3 (Definitive), mode of inheritance: AD

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Neuroblastoma, susceptibility to, 3ADOncologicSurveillance (eg, with frequent abdominal ultrasound and urinary catecholamine testing) and awareness of cancer risk may allow early diagnosis and treatment of tumors, which may reduce morbidity and mortalityOncologic18923523; 18724359; 18242317; 20301782

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the ALK gene.

  • Neuroblastoma, susceptibility to, 3 (3626 variants)
  • Hereditary cancer-predisposing syndrome (1898 variants)
  • not provided (398 variants)
  • not specified (97 variants)
  • ALK-related condition (22 variants)
  • Ovarian cancer (15 variants)
  • Familial isolated pituitary adenoma (12 variants)
  • Inborn genetic diseases (9 variants)
  • Neuroblastoma Susceptibility (7 variants)
  • Squamous cell lung carcinoma (7 variants)
  • Neuroblastoma (6 variants)
  • Non-small cell lung carcinoma (2 variants)
  • Lung adenocarcinoma (2 variants)
  • Neoplasm of brain (2 variants)
  • Diffuse midline glioma, H3 K27-altered (1 variants)
  • Diffuse pediatric-type high-grade glioma, H3-wildtype and IDH-wildtype (1 variants)
  • Lung cancer (1 variants)
  • Rhabdomyosarcoma (1 variants)
  • Multiple endocrine neoplasia, type 2a (1 variants)
  • Breast neoplasm (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the ALK gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
22
clinvar
1071
clinvar
15
clinvar
1108
missense
2
clinvar
3
clinvar
2172
clinvar
24
clinvar
12
clinvar
2213
nonsense
57
clinvar
57
start loss
2
clinvar
2
frameshift
74
clinvar
74
inframe indel
29
clinvar
1
clinvar
30
splice donor/acceptor (+/-2bp)
50
clinvar
50
splice region
98
120
4
222
non coding
43
clinvar
375
clinvar
112
clinvar
530
Total 2 3 2449 1471 139

Highest pathogenic variant AF is 0.0000131

Variants in ALK

This is a list of pathogenic ClinVar variants found in the ALK region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
2-29192809-C-T Neuroblastoma Susceptibility Uncertain significance (Jun 14, 2016)335676
2-29192817-T-G Neuroblastoma, susceptibility to, 3 Uncertain significance (Jan 13, 2018)899148
2-29192821-A-G Neuroblastoma, susceptibility to, 3 Uncertain significance (Jan 13, 2018)895024
2-29192926-G-A Neuroblastoma, susceptibility to, 3 Benign (Jan 12, 2018)335677
2-29192978-C-T Neuroblastoma, susceptibility to, 3 Uncertain significance (Jan 13, 2018)895025
2-29193035-A-G Neuroblastoma, susceptibility to, 3 Uncertain significance (Jan 13, 2018)335678
2-29193039-G-A Neuroblastoma, susceptibility to, 3 Uncertain significance (Jan 13, 2018)335679
2-29193113-G-A Neuroblastoma, susceptibility to, 3 Benign (Jun 23, 2018)335680
2-29193158-C-CCATT Neuroblastoma Susceptibility Uncertain significance (Jun 14, 2016)335681
2-29193159-C-CATTG Neuroblastoma Susceptibility Benign (Jun 14, 2018)335682
2-29193161-T-C Neuroblastoma, susceptibility to, 3 Benign/Likely benign (Dec 24, 2018)335683
2-29193171-C-G Neuroblastoma, susceptibility to, 3 Benign (Jun 23, 2018)335684
2-29193179-C-T Neuroblastoma, susceptibility to, 3 Benign (Jan 12, 2018)335685
2-29193211-TGTGCGACCGAGCTCAG-T Neuroblastoma, susceptibility to, 3 Uncertain significance (Apr 28, 2023)947158
2-29193219-CGAGCTCA-C Neuroblastoma, susceptibility to, 3 Uncertain significance (Dec 28, 2023)2706000
2-29193225-C-T Neuroblastoma, susceptibility to, 3 • Hereditary cancer-predisposing syndrome Likely benign (Oct 04, 2023)1668158
2-29193226-A-G Neuroblastoma, susceptibility to, 3 Uncertain significance (Oct 01, 2021)1383984
2-29193227-G-A Neuroblastoma, susceptibility to, 3 Likely benign (Jun 09, 2021)1595801
2-29193227-G-C Neuroblastoma, susceptibility to, 3 Uncertain significance (Dec 28, 2021)2156658
2-29193228-G-A Neuroblastoma, susceptibility to, 3 Uncertain significance (Nov 28, 2023)954390
2-29193229-G-A Hereditary cancer-predisposing syndrome Uncertain significance (Nov 11, 2023)3223916
2-29193230-C-T Neuroblastoma, susceptibility to, 3 • Hereditary cancer-predisposing syndrome Likely benign (Dec 03, 2022)1549031
2-29193231-C-A Hereditary cancer-predisposing syndrome • Neuroblastoma, susceptibility to, 3 Uncertain significance (Oct 28, 2023)1743598
2-29193232-C-T Neuroblastoma, susceptibility to, 3 • Hereditary cancer-predisposing syndrome Uncertain significance (Jan 22, 2023)2133402
2-29193232-C-CAGGCTGGTTCATGCTATTCTTGCTTTT Neuroblastoma, susceptibility to, 3 Uncertain significance (Apr 06, 2020)1038369

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
ALKprotein_codingprotein_codingENST00000389048 29728793
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
0.000003231.0012534104071257480.00162
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense0.01039199200.9990.000053510449
Missense in Polyphen319390.090.817774515
Synonymous-2.654493831.170.00002443305
Loss of Function5.562578.00.3210.00000406854

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.006200.00616
Ashkenazi Jewish0.003140.00288
East Asian0.001480.00136
Finnish0.001590.00153
European (Non-Finnish)0.001010.000950
Middle Eastern0.001480.00136
South Asian0.001420.00131
Other0.003370.00294

dbNSFP

Source: dbNSFP

Function
FUNCTION: Neuronal receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis and differentiation of the nervous system. Transduces signals from ligands at the cell surface, through specific activation of the mitogen-activated protein kinase (MAPK) pathway. Phosphorylates almost exclusively at the first tyrosine of the Y- x-x-x-Y-Y motif. Following activation by ligand, ALK induces tyrosine phosphorylation of CBL, FRS2, IRS1 and SHC1, as well as of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1. Acts as a receptor for ligands pleiotrophin (PTN), a secreted growth factor, and midkine (MDK), a PTN-related factor, thus participating in PTN and MDK signal transduction. PTN-binding induces MAPK pathway activation, which is important for the anti-apoptotic signaling of PTN and regulation of cell proliferation. MDK-binding induces phosphorylation of the ALK target insulin receptor substrate (IRS1), activates mitogen-activated protein kinases (MAPKs) and PI3-kinase, resulting also in cell proliferation induction. Drives NF-kappa-B activation, probably through IRS1 and the activation of the AKT serine/threonine kinase. Recruitment of IRS1 to activated ALK and the activation of NF-kappa-B are essential for the autocrine growth and survival signaling of MDK. {ECO:0000269|PubMed:11121404, ECO:0000269|PubMed:11278720, ECO:0000269|PubMed:11387242, ECO:0000269|PubMed:11809760, ECO:0000269|PubMed:12107166, ECO:0000269|PubMed:12122009, ECO:0000269|PubMed:15226403, ECO:0000269|PubMed:15908427, ECO:0000269|PubMed:16317043, ECO:0000269|PubMed:16878150, ECO:0000269|PubMed:17274988}.;
Disease
DISEASE: Note=A chromosomal aberration involving ALK is found in a form of non-Hodgkin lymphoma. Translocation t(2;5)(p23;q35) with NPM1. The resulting chimeric NPM1-ALK protein homodimerize and the kinase becomes constitutively activated. The constitutively active fusion proteins are responsible for 5-10% of non-Hodgkin lymphomas.; DISEASE: Note=A chromosomal aberration involving ALK is associated with inflammatory myofibroblastic tumors (IMTs). Translocation t(2;11)(p23;p15) with CARS; translocation t(2;4)(p23;q21) with SEC31A.; DISEASE: Note=A chromosomal aberration involving ALK is associated with anaplastic large-cell lymphoma (ALCL). Translocation t(2;17)(p23;q25) with ALO17.; DISEASE: Neuroblastoma 3 (NBLST3) [MIM:613014]: A common neoplasm of early childhood arising from embryonic cells that form the primitive neural crest and give rise to the adrenal medulla and the sympathetic nervous system. {ECO:0000269|PubMed:18724359, ECO:0000269|PubMed:18923523, ECO:0000269|PubMed:18923525, ECO:0000269|PubMed:21242967}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=The ALK signaling pathway plays an important role in glioblastoma, the most common malignant brain tumor of adults and one of the most lethal cancers. It regulates both glioblastoma migration and growth.; DISEASE: Note=A chromosomal aberration involving ALK is found in one subject with colorectal cancer. Translocation t(2;2)(p23.1;p23.3). A 5 million base pair tandem duplication generates an in-frame WDCP-ALK gene fusion. {ECO:0000269|PubMed:22327622}.;
Pathway
Non-small cell lung cancer - Homo sapiens (human);Pathways in cancer - Homo sapiens (human);Differentiation Pathway;MET in type 1 papillary renal cell carcinoma;Disease;Gene expression (Transcription);Generic Transcription Pathway;Interactions of Rev with host cellular proteins;Host Interactions of HIV factors;HIV Infection;RNA Polymerase II Transcription;Infectious disease;Nucleosome assembly;IL-7 signaling;Chromosome Maintenance;TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain;TP53 Regulates Transcription of Cell Cycle Genes;JAK STAT pathway and regulation;Deposition of new CENPA-containing nucleosomes at the centromere;EPO signaling;Transcriptional Regulation by TP53;TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation;Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors;Nuclear import of Rev protein;Cell Cycle;VEGF (Consensus)

Recessive Scores

pRec
0.419

Intolerance Scores

loftool
0.202
rvis_EVS
-2.24
rvis_percentile_EVS
1.3

Haploinsufficiency Scores

pHI
0.215
hipred
Y
hipred_score
0.575
ghis
0.423

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
N
gene_indispensability_pred
E
gene_indispensability_score
0.802

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumHigh
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Alk
Phenotype
integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); growth/size/body region phenotype; endocrine/exocrine gland phenotype; homeostasis/metabolism phenotype; vision/eye phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); reproductive system phenotype; neoplasm; pigmentation phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); respiratory system phenotype; skeleton phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan);

Zebrafish Information Network

Gene name
alk
Affected structure
hindbrain
Phenotype tag
abnormal
Phenotype quality
apoptotic

Gene ontology

Biological process
activation of MAPK activity;signal transduction;transmembrane receptor protein tyrosine kinase signaling pathway;cell population proliferation;phosphorylation;peptidyl-tyrosine phosphorylation;hippocampus development;adult behavior;swimming behavior;NIK/NF-kappaB signaling;regulation of cell population proliferation;regulation of apoptotic process;regulation of neuron differentiation;protein autophosphorylation;neuron development;positive regulation of NF-kappaB transcription factor activity;regulation of dopamine receptor signaling pathway;response to environmental enrichment
Cellular component
plasma membrane;integral component of plasma membrane;protein-containing complex;receptor complex;extracellular exosome
Molecular function
NF-kappaB-inducing kinase activity;protein tyrosine kinase activity;transmembrane receptor protein tyrosine kinase activity;protein binding;ATP binding;identical protein binding